News Story: Full Text
Sponsored By
Orbus Therapeutics Inc Clinical Trial for Recurrent Anaplastic Astrocytomas
Please Click On The Above Banner For More Details
Braintumor Website

YMI BioSciences Gets OK to Import Drug

Al Musella's Comments: (This is his personal views and are not necessarily the views of the Musella Foundation!)


Posted on: 09/29/2006

Sept. 25, 2006, 6:48AM
YMI BioSciences Gets OK to Import Drug

NEW YORK — YM BioSciences Inc., which focuses on oncology and acute care products, said Monday it received approval from the Office of Foreign Assets Control of the Treasury Department to import nimotuzumab.

Nimotuzumab, a monoclonal antibody that targets the epidermal growth factor receptor, was developed at the Center for Molecular Immunology affiliated with the University of Havana.

The license granted lets YM start clinical trials in children with pontine glioma, or inoperable malignant brain tumors.

The commercialization of the drug would require an additional license from OFAC, the company said.

Click HERE to return to brain tumor news headlines

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557